Beckman Coulter has launched its Access SARS-CoV-2 IgG II assay in countries accepting the CE mark. The new Access SARS-CoV-2 IgG II assay quantitatively measures a patient’s level of antibodies in response to a previous SARS-CoV-2 infection.
The ability to establish a quantitative baseline to evaluate an individual’s immune response to the SARS-CoV-2 virus allows clinicians to assess relative changes of an individual’s immune response to the virus over time based on a numerical value. The assay may also help researchers as they begin to understand the levels of IgG antibodies needed to be considered protective.
The Access SARS-CoV-2 IgG II quantitative assay is the latest addition to Beckman Coulter’s full suite of testing solutions designed to provide valuable information to clinicians in their fight against COVID-19. Beckman Coulter also recently launched an automated SARS-CoV-2 antigen test in the USA. While several point-of-care (POC) antigen tests are now available to help increase testing beyond current levels, POC tests come with workflow challenges when scaled to large patient populations. Beckman Coulter’s SARS CoV-2 Antigen test is designed to address these challenges. The organisation can deliver up to 25 million tests per month, and the assay separates sample collection and processing, enabling test providers to use the existing infrastructure and workflows.
Results of the new Access SARS-CoV-2 IgG II test are delivered quickly on Beckman Coulter’s immunoassay analysers, including the DxI 800 high-throughput analyser, which is capable of processing up to 200 samples per hour.
More information on Beckman Coulter’s full suite of testing solutions or its commitment to the fight against COVID-19 is available online.
